LTB4-Driven Inflammation and Increased Expression of ALOX5/ACE2 During Severe COVID-19 in Individuals With Diabetes

doi:10.2337/db20-1260

PMC full text:

Diabetes. 2021 Sep; 70(9): 2120–2130.

Published online 2021 Jun 15. doi: 10.2337/db20-1260

Copyright/LicenseRequest permission to reuse: Copyright © 2021 by the American Diabetes Association
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.

<< PrevFigure 4Next >>

Figure 4

An external file that holds a picture, illustration, etc.
Object name is db201260f4.jpg

Increased systemic levels of LTB₄ in patients in the DM group, with COVID-19. Levels of LTB4 (A), IL-6 (B), and TNF-α (C) in plasma samples from DM and NDM patients affected by COVID-19. Plasma levels of LTB4 (D), IL-6 (E), and TNF-α (F) in NDM and DM patients with COVID-19 categorized by hospitalization type: clinical beds (CB) or intensive care units (ICU). Data are means. *P < 0.05.

Figure 4

Images in this article

Click on the image to see a larger version.